| All Releases |
|---|
 |
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
May 7, 2008
|
10.5 KB
|
| |
MENLO PARK, Calif., May 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a webcast and conference call to review the new CUSTOM III data immediately f...
|
|
|
XTENT Announces First Quarter 2008 Financial Results
Apr 28, 2008
|
11.0 KB
|
| |
MENLO PARK, Calif., April 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the first quarter ended March 31, 2008.
The company reported a net loss of $12.5 million, or $0.54 per share, for the first quarter of 2008, compared to a net loss of $7.9 million, or $0.55 per sha...
|
|
|
XTENT to Present at Cowen and Company's 28th Annual Health Care Conference
Mar 12, 2008
|
5.5 KB
|
| |
MENLO PARK, Calif., March 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that Gregory D. Casciaro, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Tuesday, March 18, 2008 at 9:30 a.m. Eastern. This event will be held at the Boston...
|
|
|
XTENT Announces 2007 Financial Results
Feb 19, 2008
|
12.5 KB
|
| |
MENLO PARK, Calif., Feb 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the fourth quarter and year ended December 31, 2007.
The company reported a net loss and net loss attributable to common stockholders of $11.9 million, or $0.52 per share, for the fourth quarter of 2...
|
|
|
XTENT Announces 2007 Financial Results Conference Call
Feb 12, 2008
|
6.2 KB
|
| |
MENLO PARK, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) announced that it will report its financial results for 2007 after market close on Tuesday, February 19, 2008. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gr...
|
|
|
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
Dec 27, 2007
|
8.4 KB
|
| |
MENLO PARK, Calif., Dec 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT), the developer of customizable drug-eluting stent (DES) systems, today announced that it has submitted its application to the designated European Notified Body for CE Mark approval of its Custom NX DES System.
XTENT's CE Mark applicatio...
|
|
|
XTENT to Present at Three Upcoming Investor Conferences
Nov 15, 2007
|
6.5 KB
|
| |
MENLO PARK, Calif., Nov 15, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it will present at three upcoming investor conferences. The presentation details are as follows:
Piper Jaffray 19th Annual Health Care Conference
Tuesday, November 27 at 8:30 a.m. ET
The Pierre ...
|
|
|
XTENT Announces Third Quarter 2007 Financial Results
Nov 2, 2007
|
9.3 KB
|
| |
MENLO PARK, Calif., Nov 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the third quarter ended September 30, 2007.
The company reported a net loss of $9.5 million, or $0.42 per share, for the third quarter of 2007, compared to a net loss of $8.0 million, or $2.84 per sh...
|
|
|
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Oct 22, 2007
|
11.5 KB
|
| |
WASHINGTON, Oct 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow-up data from the CUSTOM I and CUSTOM II single-arm prospective studies evaluating the safety and efficacy of its Custom NX(R) drug-eluting stent system in patients with coronary artery disease.
At one-y...
|
|
|
XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
Oct 16, 2007
|
8.7 KB
|
| |
MENLO PARK, Calif., Oct 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX® drug-eluting stent (DES) system will be presented at the Ca...
|
|
|
XTENT to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007
Sep 12, 2007
|
5.6 KB
|
| |
MENLO PARK, Calif., Sept 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that Timothy D. Kahlenberg, Chief Financial Officer, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on Monday, September 17, 2007 at 10:45 a.m. Pacific. This event will be held at the Mark Hopkins...
|
|
|
XTENT Appoints Michael L. Eagle to Board of Directors
Aug 13, 2007
|
7.6 KB
|
| |
MENLO PARK, Calif., Aug 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) announced today that Michael L. Eagle, former Vice President, Manufacturing, at Eli Lilly and Company, has been appointed to the company's Board of Directors.
"We are very fortunate to have Mike Eagle join our Board of Directors as we r...
|
|
|
XTENT Announces Second Quarter 2007 Financial Results
Aug 7, 2007
|
12.4 KB
|
| |
MENLO PARK, Calif., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the quarter ended June 30, 2007.
The company reported a net loss of $9.5 million for the second quarter of 2007, compared to a net loss of $5.7 million for the same period last year. The net loss att...
|
|
|
XTENT Announces Second Quarter 2007 Financial Results Call and Extension of Lock-Up Agreements
Jul 25, 2007
|
7.0 KB
|
| |
MENLO PARK, Calif., July 25, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) announced that it will report its financial results for the second quarter 2007 after market close on Tuesday, August 7, 2007. The company will hold a conference call the same day at 2 p.m. Pacific Time (5 p.m. Eastern Time). The call will...
|
|
|
XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
May 22, 2007
|
11.4 KB
|
| |
BARCELONA and MENLO PARK, Calif., May 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) announces positive six-month follow-up data from the CUSTOM II clinical trial, which assessed the safety and efficacy of the company's investigational Custom NX(R) drug-eluting stent (DES) system for the treatment of long and ...
|
|
|
XTENT Announces Webcast and Conference Call to Discuss CUSTOM II Trial Six-Month Data Presented At EuroPCR Meeting
May 22, 2007
|
7.1 KB
|
| |
MENLO PARK, Calif., May 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT), developer of customizable drug-eluting stent (DES) systems, will host an analyst webcast, slide presentation and telebriefing to review the CUSTOM II six-month data Tuesday, May 22 at 2:00p.m. EDT (8:00p.m. CEST).
The event will follow...
|
|
|
XTENT Announces Acceptance of Custom II Trial Data for Late Breaking Clinical Trial Session at EuroPCR
May 9, 2007
|
9.0 KB
|
| |
MENLO PARK, Calif., May 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 6-month follow-up data from the CUSTOM II trial will be presented at EuroPCR, taking place May 22 to 25 in Barcelona. The company will also hold an analyst teleconference to review the CUSTOM II data following the late-b...
|
|
|
XTENT Announces First Quarter 2007 Financial Results
May 8, 2007
|
8.9 KB
|
| |
MENLO PARK, Calif., May 8, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the first quarter ended March 31, 2007.
The company reported a net loss of $7.9 million for the first quarter of 2007, compared to a net loss of $4.1 million for the same period last year. The net los...
|
|
|
XTENT Announces First Quarter 2007 Financial Results Call
May 1, 2007
|
6.4 KB
|
| |
MENLO PARK, Calif., May 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT (Nasdaq: XTNT) announced that it will report its financial results for the first quarter 2007 after market close on Tuesday, May 8, 2007. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted ...
|
|
|
XTENT Announces Successful Clinical Use of Enhanced Custom NX System in Ongoing CUSTOM III Feasibility Trial
Apr 3, 2007
|
9.9 KB
|
| |
MENLO PARK, Calif., Apr 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- XTENT, Inc. (Nasdaq: XTNT) today announced the enhanced configuration of the company's Custom NX(TM) Drug Eluting Stent (DES) system was used successfully in its ongoing CUSTOM III clinical trial in Europe. The company also announced that its U.S. pivotal trial is on...
|
|
|
